文献速递关节外科

全髋或全膝关节置换术前一年内未控制的糖尿病与术前糖尿病优化后相似的围手术期血糖控制、早期并发症率及5年再手术率相关

Uncontrolled Diabetes Mellitus in the Year Prior to Total Hip or Knee Arthroplasty Is Associated with Similar Perioperative Glucose Control, Early Complication Rates, and 5-Year Reoperation Rates after Preoperative Diabetes Mellitus Optimization.
PubMed 文献 · J Arthroplasty · 2025-12-18

该回顾性单中心研究纳入585例接受初次全髋或全膝关节置换的糖尿病患者,比较术前一年内需糖尿病优化(HbA1C≥8%)者164例与糖尿病控制者421例,发现两组围手术期血糖中位数和峰值、90天并发症率及再手术率均相似,术前需优化糖尿病未影响上述结局。

要点

  • 术前需糖尿病优化者与糖尿病控制者的术后早期血糖中位数和峰值相似。
  • 术前需优化糖尿病者90天并发症率与糖尿病控制者相似(OR 1.67,95%CI 0.91-2.88;P=0.10)。
  • 两组再手术率相似(OR 1.60,95%CI 0.59-4.36;P=0.35)。

核心结论

  • 本研究提示,需要糖尿病优化并不影响围手术期血糖控制、术后并发症或再手术,提示在全髋和全膝关节置换术前优化血红蛋白A1C的努力是值得的。

研究设计与样本

  • 回顾性单中心分析,纳入接受初次全关节置换且诊断为糖尿病(血红蛋白A1C大于6.5%)的患者585例。
  • 术前一年内需糖尿病优化(血红蛋白A1C≥8.0%)者164例与糖尿病控制者421例进行比较,所有患者术前血红蛋白A1C均小于8%。

主要发现

  • 术后早期血清葡萄糖中位数和峰值在糖尿病控制者与优化者之间相似。
  • 术前一年内较高的血红蛋白A1C和峰值血红蛋白A1C与较差的血清葡萄糖中位数和峰值相关。
  • 需糖尿病优化者与糖尿病控制者的90天并发症率相似(OR 1.67,95%CI 0.91-2.88;P=0.10)。
  • 二甲双胍使用与较低的并发症率独立相关。
  • 需术前糖尿病优化者与糖尿病控制者的再手术率相似(OR 1.60,95%CI 0.59-4.36;P=0.35)。

关键数值与推荐

  • 糖尿病定义为血红蛋白A1C大于6.5%。
  • 需糖尿病优化定义为术前一年内血红蛋白A1C≥8.0%。
  • 所有患者术前血红蛋白A1C均小于8%。

临床怎么用

  • 本研究提示,需要糖尿病优化不影响围手术期血糖控制、术后并发症或再手术,提示在全髋和全膝关节置换术前优化血红蛋白A1C的努力是值得的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative glycemic control is considered a modifiable risk factor prior to primary total hip and total knee arthroplasty; however, it is still unknown whether preoperatively optimizing hemoglobin A1C values affects perioperative glucose control or postoperative complications. The purpose of this study was to compare patients who required preoperative diabetes mellitus (DM) optimization in the year prior to surgery (defined as hemoglobin A1C ≥ 8%) versus patients who had DM who did not require preoperative DM optimization to compare (1) postoperative glycemic control and (2) 90-day complications and incidence of revision arthroplasty. METHODS: This was a retrospective single-center analysis. Patients undergoing primary total joint arthroplasty who had a diagnosis of DM (hemoglobin A1C greater than 6.5%) were eligible for inclusion (N = 585). Patients who had previously uncontrolled DM requiring optimization (hemoglobin A1C ≥ 8.0%) in the year prior to surgery (N = 164) were compared to patients who had controlled DM (N = 421). All patients had hemoglobin A1C less than 8% preoperatively. Outcomes included median and peak perioperative glycemic control (postoperative day zero to two), 90-day complications, and incidence of revision arthroplasty at the final follow-up (mean 64 months). Multivariable logistic regressions evaluated associations of underlying preoperative demographic and treatment characteristics with outcomes. RESULTS: Early postoperative median serum glucose and peak serum glucose were similar between patients who had controlled versus optimized DM. Higher preoperative hemoglobin A1C and peak hemoglobin A1C in the year prior to surgery were associated with worse median and peak serum glucose. The 90-day complication rates were similar in patients needing DM optimization versus controlled DM patients (odds ratio 1.67, 95% confidence interval 0.91 to 2.88; P = 0.10). Metformin use was independently associated with lower complication rates. Reoperations were similar between patients requiring preoperative DM optimization versus controlled DM (odds ratio 1.60, 95% confidence interval 0.59 to 4.36, P = 0.35). CONCLUSIONS: This study suggests that the need for DM optimization does not affect perioperative glucose control, postoperative complications, or reoperations, suggesting that efforts to optimize hemoglobin A1C prior to total hip and total knee arthroplasty are warranted.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Umelo J, Jubril A, Burger PU, et al. Uncontrolled Diabetes Mellitus in the Year Prior to Total Hip or Knee Arthroplasty Is Associated with Similar Perioperative Glucose Control, Early Complication Rates, and 5-Year Reoperation Rates after Preoperative Diabetes Mellitus Optimization. J Arthroplasty. 2025. PMID: 41421714. doi:10.1016/j.arth.2025.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。